23andMe (NASDAQ:ME – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($1.02) earnings per share for the quarter, Zacks reports. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.
23andMe Price Performance
Shares of NASDAQ ME opened at $3.50 on Thursday. The firm’s 50-day moving average is $3.47 and its two-hundred day moving average is $5.35. 23andMe has a 12-month low of $2.65 and a 12-month high of $16.52. The company has a market capitalization of $91.29 million, a PE ratio of -0.14 and a beta of 1.14.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 23andMe in a research report on Saturday, January 18th.
23andMe Company Profile
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Read More
- Five stocks we like better than 23andMe
- What Does a Stock Split Mean?
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
- Using the MarketBeat Dividend Yield Calculator
- ASML: Strengths and Upside Remain Despite DeepSeek Worries
- 3 Warren Buffett Stocks to Buy Now
- Royal Caribbean Soars, But Smooth Sailing Isn’t Guaranteed
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.
